NovaGo Therapeutics is a Swiss biotech company developing human antibody therapeutics to promote regeneration after cerebral stroke,
NovaGo Therapeutics has raised €8.9M across 1 funding round from 2 investors, most recently a Series A round in Jan 2019. Based in Schlieren, Switzerland; active in Healthtech. Data as of 7 Aug 2026.
Timing: dormant vs cohort gap · momentum unknown. Funding-only estimates, not predictions and not investment advice — see signals.
| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2019-01-01 | Series A |
| €8.9M |
| Neurimmune Holding,Pureos Bioventures |
| View deal → |
